Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.73 |
| ▸ | KDR | P35968 | 5/20 | 0.73 |
| ▸ | FBP1 | P09467 | 2/20 | 0.73 |
| ▸ | AURKA | O14965 | 1/20 | 0.73 |
| ▸ | INSR | P06213 | 1/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.73 |
| ▸ | FLT4 | P35916 | 1/20 | 0.73 |
| ▸ | CLK1 | P49759 | 1/20 | 0.73 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.73 |
| ▸ | TEK | Q02763 | 1/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20305537 | 0.92 | EGFR (0.70) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL643027 | 0.91 | EGFR (0.79) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL641806 | 0.89 | EGFR (0.79) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL643422 | 0.89 | EGFR (0.79) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL4342528 | 0.89 | EGFR (0.79) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL15217643 | 0.89 | EGFR (0.79) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL15217637 | 0.89 | EGFR (0.79) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL15217638 | 0.89 | EGFR (0.79) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL22336753 | 0.88 | FBP1 (0.92) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL642542 | 0.87 | HDAC3 (0.83) | EGFRERBB2KDRFBP1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2634178-B1 | QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF | CHINESE ACAD INST CHEMISTRY (CN) | 2016-08-24 | — | — | EP | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150274678-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-01 | — | — | US | disclosed |
| US-9108929-B2 | Quinazoline based EGFR inhibitors | CURIS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9024024-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-8975401-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2190287-B1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8846912-B2 | Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2009035718-A1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076022-A1 | epidermal growth factor receptor tyrosine kinase (EGFR-TK) and histone deacetylase inhibitors such as 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide, used as anticarcinogenic agents | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | CURIS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080125448-A1 | Quinazoline Based EGFR Inhibitors Containing a Zinc Binding Moiety | CURIS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008033748-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033749-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076022-A1 | epidermal growth factor receptor tyrosine kinase (EGFR-TK) and histone deacetylase inhibitors such as 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide, used as anticarcinogenic agents | EGFR, HDAC1, HDAC8 | EGFR 1/4885ERBB2 7/4885KDR 379/4885 |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | EGFR 2358/4885ERBB2 2794/4885KDR 2667/4885 |
| US-20080125448-A1 | Quinazoline Based EGFR Inhibitors Containing a Zinc Binding Moiety | EGFR, ERBB2, ERBB4 | EGFR 1/4885ERBB2 2/4885KDR 75/4885 |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | HDAC1, HDAC8, EGFR | EGFR 3/4885ERBB2 9/4885KDR 559/4885 |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC6 | EGFR 1/4885ERBB2 9/4885KDR 360/4885 |
| US-20150274678-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC5 | EGFR 1/4885ERBB2 5/4885KDR 330/4885 |
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, ERBB4, HDAC5 | EGFR 1/4885ERBB2 7/4885KDR 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.